TNF抑制剂在极早期中轴型脊柱关节炎中的有效性:SCQM登记研究
基于瑞士SCQM登记中3324例中轴型脊柱关节炎患者,按背痛病程≤1年(极早期,n=441)、>1年且≤2年(早期,n=218)和>2年(已确立,n=2575)分组,比较首次TNF抑制剂治疗1年后达到ASDAS<2.1的概率及药物留存。调整混杂因素后,极早期与已确立患者达到ASDAS<2.1的OR为1.08(95%CI 0.70-1.68),停药HR为1.05(95%CI 0.84-1.31),均无显著差异。结论提示极早期中轴型脊柱关节炎患者使用TNF抑制剂并未显示更优的有效性。
要点
- 极早期axSpA定义为背痛病程≤1年,本研究中占441/3324例。
- 极早期与已确立axSpA患者TNFi治疗1年达到ASDAS<2.1的OR为1.08(95%CI 0.70-1.68)。
- 极早期与已确立axSpA患者TNFi停药HR为1.05(95%CI 0.84-1.31),无显著差异。
核心结论
- 极早期中轴型脊柱关节炎患者使用首个TNF抑制剂,在1年时达到低疾病活动度(ASDAS<2.1)的概率及药物留存与已确立患者无显著差异。
研究设计与样本
- 基于瑞士SCQM登记的前瞻性纵向观察性研究,纳入3324例有背痛病程数据的中轴型脊柱关节炎患者。
- 按背痛病程分为极早期(≤1年,n=441)、早期(>1年且≤2年,n=218)和已确立(>2年,n=2575)三组。
- 采用调整logistic回归比较1年时ASDAS<2.1的概率,用多因素调整Cox比例风险模型分析药物留存,缺失数据通过链式方程多重插补处理。
主要发现
- 极早期患者中客观炎症体征更常见。
- 调整年龄、性别、HLA-B27状态、教育、BMI、吸烟、ASDAS及MRI骶髂关节炎症后,极早期与已确立患者达到ASDAS<2.1的OR为1.08(95%CI 0.70-1.68)。
- 极早期与已确立患者TNFi停药的HR为1.05(95%CI 0.84-1.31),无显著差异。
关键数值与推荐
- 极早期axSpA定义为背痛病程≤1年,早期为>1年且≤2年,已确立为>2年。
- 低疾病活动度定义为ASDAS<2.1。
- 极早期、早期和已确立组中首次启动TNFi的患者比例分别为31%、38%和36%。
临床怎么用
- 对于背痛病程≤1年的极早期中轴型脊柱关节炎患者,启动TNF抑制剂不应以追求比已确立患者更优的疗效为目的。
- 临床决策时需结合客观炎症体征、MRI表现及整体病情评估,而非仅依据极早期病程。
局限性
- 本研究为观察性登记研究,存在混杂因素和适应证偏倚可能。
- 极早期和早期组样本量相对较小(分别为441例和218例)。
- 缺失数据虽经多重插补处理,仍可能影响结果稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterise patients with 'very early' axial spondyloarthritis (axSpA), defined as a duration ≤1 year of back pain and to determine the effectiveness of a first tumour necrosis factor inhibitor (TNFi) in very early versus established axSpA in a large observational registry. METHODS: We included a total of 3324 patients with axSpA from the Swiss Clinical Quality Management in Rheumatic Diseases registry with available data on duration of back pain (≤1 year=very early axSpA, n=441; >1 year and ≤2 years=early axSpA, n=218; >2 years=established axSpA, n=2575). A first TNFi was started in 31%, 38% and 36% of patients with very early, early and established axSpA. Adjusted logistic regression models were used to compare the probability of achieving low disease activity status according to the Axial Spondyloarthritis Disease Activity Score (ASDAS <2.1) at 1 year. Drug survival was analysed with multiple-adjusted Cox proportional hazards models. Missing data were handled using multiple imputation by chained equations. RESULTS: Objective signs of inflammation were more prevalent in very early disease. No difference was found regarding the achievement of ASDAS <2.1 after adjustment for age, sex, human leucocyte antigen-B27 status, education, body mass index, smoking, ASDAS and sacroiliac inflammation on MRI (OR 1.08, 95% CI 0.70 to 1.68 in very early vs established axSpA). Similarly, no significant difference in TNFi retention was found in very early versus established axSpA (HR for drug discontinuation 1.05, 95% CI 0.84 to 1.31). CONCLUSION: We found no evidence for a better effectiveness of TNFi in patients with very early versus established axSpA.
引用
- Bachmann M, Götschi A, Steimer A, et al. Effectiveness of TNF inhibitors in patients with very early axial spondyloarthritis, defined as duration of ≤1 year of back pain: longitudinal observational data from the SCQM registry. RMD Open. 2026. PMID: 41786464. doi:10.1136/rmdopen-2025-006647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。